Since KDs target the metabolic shift from OXPHOS to glycolysis in tumor cells, it is rational to hypothesize that the tumors with high glycolytic enzyme and low ketolytic enzyme expression may benefit from KDT, whereas tumor cells with highly expressed ketolytic enzymes may actively consume ketone bodies as an energy source, leading to the KDT resistance. The gene discussed is HK1; the disease is neoplasm.